Imdusiran

N/A

Report date: 2026/04/28 18:01:31
NME

Base Information

Drug NameImdusiran
Drug Alias NameAcetylgalactosamine (GalNAc) conjugate RNA interference (RNAi) therapeutic (Arbutus Biopharma)GalNAc-siRNA (Arbutus Biopharma)AB-729ARB-270729(Arbutus Biopharma )
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Small Interfering RNA
Mechanisms of ActionHepatitis B virus replication inhibitorsRNA interferenceHBsAg inhibitors +[4] 
TargetsHepatitis B Surface AntigensAsialoglycoprotein receptor
Therapy Area/IndicationsHepatitis B, ChronicHepatitis B
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBulgariaCanadaUnited States +[16] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaIND
Originator CompaniesArbutus Biopharma Corp
China Registration ClassN/A

Develop Information

Active CompaniesArbutus Biopharma CorpUniversity Of Maryland, BaltimoreQilu Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsHepatitis B, ChronicHepatitis B
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A